Non-viral siRNA delivery to the lung

SiRNAs exert their biological effect by guiding the degradation of their cognate mRNA sequence, thereby shutting down the corresponding protein production (gene silencing by RNA interference or RNAi). Due to this property, siRNAs are emerging as promising therapeutic agents for the treatment of inhe...

Full description

Saved in:
Bibliographic Details
Published in:Advanced drug delivery reviews 2007-03, Vol.59 (2), p.124-133
Main Authors: Thomas, Mini, Lu, James J., Chen, Jianzhu, Klibanov, Alexander M.
Format: Article
Language:English
Subjects:
Animals
Drug Delivery Systems - methods
Drug Delivery Systems - trends
Gene Silencing
Humans
Lung
Lung - metabolism
Lung - pathology
Lung Diseases - genetics
Lung Diseases - therapy
RNA interference
RNA, Small Interfering - administration & dosage
RNA, Small Interfering - genetics
RNA, Small Interfering - pharmacokinetics
siRNA delivery
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SiRNAs exert their biological effect by guiding the degradation of their cognate mRNA sequence, thereby shutting down the corresponding protein production (gene silencing by RNA interference or RNAi). Due to this property, siRNAs are emerging as promising therapeutic agents for the treatment of inherited and acquired diseases, as well as research tools for the elucidation of gene function in both health and disease. Because of their lethality and prevalence, lung diseases have attracted particular attention as targets of siRNA-mediated cures. In addition, lung is accessible to therapeutic agents via multiple routes, e.g., through the nose and the mouth, thus obviating the need for targeting and making it an appealing target for RNAi-based therapeutic strategies. The clinical success of siRNA-mediated interventions critically depends upon the safety and efficacy of the delivery methods and agents. Delivery of siRNAs relevant to lung diseases has been attempted through multiple routes and using various carriers in animal models. This review focuses on the recent progress in non-viral delivery of siRNAs for the treatment of lung diseases, particularly infectious diseases. The rapid progress will put siRNA-based therapeutics on fast track to the clinic.
ISSN:0169-409X
1872-8294
DOI:10.1016/j.addr.2007.03.003